Sustained 'vigilance and money' necessary to fight malaria

With the RTS,S malaria vaccine trial results showing "moderate" success, helping to reignite "optimism about eradicating malaria entirely," "there are other big hurdles still to surmount," a New York Times editorial states. "There are hints that the protection may wane over time and results from administering a booster shot won't be known until 2014," and side effects could be a concern, the editorial writes.

"If final results of this ongoing study, which involves more than 15,000 children in all, show that the vaccine is safe and effective, the goal is to deploy it in 2015," the editorial notes, concluding, "But it will take vigilance and money to stay ahead of resistant mosquitoes and parasites" (10/23).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Study finds artemisinin resistance in African children with severe malaria